Cash flow AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 09:02:28 2026-04-17 am EDT			5-day change	1st Jan Change
14,944.00 ^GBX	+0.55%		-2.21%	+8.01%

Apr. 16	AIM ImmunoTech Starts Late-Stage Trial of Ampligen in Pancreatic Cancer	MT
Apr. 16	AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP	CI

86306df26d65d95ee.8MZZdF9avY-X4eUnWyR2T4_GLeRNq9oFUBLiSfp5X8c.wpYcPjAZ_9fcsdcKIhJGHeaVQ7sMm6NfFVy4BJcYaorA62FDKSnH38ep1Q

Published financial data: ASTRAZENECA PLC

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	37.42B	44.35B	45.81B	54.07B	58.74B
Other Revenues, Total	-	-	-	-	-
Total Revenues	37.42B	44.35B	45.81B	54.07B	58.74B
Cost of Goods Sold, Total	9.8B	8.62B	8.04B	9.64B	10.75B
Gross Profit	27.62B	35.73B	37.77B	44.44B	47.99B
Selling General & Admin Expenses, Total	14.46B	17.47B	18.02B	19.45B	20.07B
R&D Expenses	8.55B	9.53B	10.3B	12.24B	13.85B
Other Operating Expenses	-207M	-231M	-987M	-190M	-222M
Other Operating Expenses, Total	22.81B	26.77B	27.34B	31.51B	33.7B
Operating Income	4.81B	8.96B	10.43B	12.93B	14.29B
Interest Expense, Total	-776M	-917M	-1.22B	-1.4B	-1.36B
Interest And Investment Income	43M	81M	301M	345M	360M
Net Interest Expenses	-733M	-836M	-918M	-1.06B	-1B
Income (Loss) On Equity Invest.	-64M	-5M	-12M	-28M	-7M
Currency Exchange Gains (Loss)	-20M	-16M	-34M	-42M	-31M
Other Non Operating Income (Expenses)	-478M	-370M	-292M	-134M	-247M
EBT, Excl. Unusual Items	3.52B	7.74B	9.18B	11.67B	13B
Restructuring Charges	-1.28B	-717M	-467M	-1.15B	-237M
Merger & Related Restructuring Charges	-2.44B	-3.57B	-137M	-	-25M
Gain (Loss) On Sale Of Investments	776M	-	-	-	-
Gain (Loss) On Sale Of Assets	509M	216M	292M	60M	154M
Asset Writedown	-2.07B	-241M	-434M	-1.57B	-230M
Legal Settlements	-48M	-789M	-1.01B	-48M	-218M
Other Unusual Items	774M	-133M	-520M	-260M	-44M
EBT, Incl. Unusual Items	-265M	2.5B	6.9B	8.69B	12.4B
Income Tax Expense	-380M	-792M	938M	1.65B	2.17B
Earnings From Continuing Operations	115M	3.29B	5.96B	7.04B	10.23B
Net Income to Company	115M	3.29B	5.96B	7.04B	10.23B
Minority Interest	-3M	-5M	-6M	-6M	-8M
Net Income - (IS)	112M	3.29B	5.96B	7.04B	10.22B
Net Income to Common Incl Extra Items	112M	3.29B	5.96B	7.04B	10.22B
Net Income to Common Excl. Extra Items	112M	3.29B	5.96B	7.04B	10.22B
Per Share Items
Net EPS - Basic	0.08	2.12	3.84	4.54	6.6
Basic EPS - Continuing Operations	0.08	2.12	3.84	4.54	6.6
Basic Weighted Average Shares Outstanding	1.42B	1.55B	1.55B	1.55B	1.55B
Net EPS - Diluted	0.08	2.11	3.81	4.5	6.54
Diluted EPS - Continuing Operations	0.08	2.11	3.81	4.5	6.54
Diluted Weighted Average Shares Outstanding	1.43B	1.56B	1.56B	1.56B	1.56B
Normalized Basic EPS	1.55	3.12	3.7	4.7	5.24
Normalized Diluted EPS	1.54	3.1	3.67	4.66	5.2
Dividend Per Share	2.87	2.9	2.9	3.1	3.2
Payout Ratio	3.44K	132.72	75.25	65.8	47.39
American Depositary Receipts Ratio (ADR)	0.08	0.08	0.08	0.08	0.08
Supplemental Items
EBITDA	8.62B	13.9B	15.01B	17.57B	19.28B
EBITA	7.89B	13.04B	14.28B	16.77B	18.4B
EBIT	4.81B	8.96B	10.43B	12.93B	14.29B
EBITDAR	8.62B	-	-	-	-
Total Revenues (As Reported)	37.42B	44.35B	45.81B	54.07B	58.74B
Effective Tax Rate - (Ratio)	143.4	-31.67	13.6	18.99	17.49
Total Current Taxes	1.2B	1.64B	2.44B	2.44B	2.33B
Total Deferred Taxes	-1.58B	-2.43B	-1.51B	-795M	-164M
Normalized Net Income	2.2B	4.83B	5.73B	7.29B	8.12B
Interest on Long-Term Debt	22M	24M	33M	61M	80M
Non-Cash Pension Expense	38M	42M	37M	64M	30M
Supplemental Operating Expense Items
Selling and Marketing Expenses	446M	534M	539M	555M	579M
Research And Development Expense From Footnotes	9.82B	9.84B	11.02B	13.67B	14.31B
Net Rental Expense, Total	6M	-	-	-	-
Imputed Operating Lease Interest Expense	1.33M	-	-	-	-
Imputed Operating Lease Depreciation	4.67M	-	-	-	-
Stock-Based Comp., Other (Total)	615M	619M	579M	660M	719M
Total Stock-Based Compensation	615M	619M	579M	660M	719M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	6.33B	6.17B	5.84B	5.49B	5.71B
Short Term Investments	53M	64M	-	-	-
Trading Asset Securities, Total	16M	14M	20M	37M	8M
Total Cash And Short Term Investments	6.4B	6.24B	5.86B	5.52B	5.72B
Accounts Receivable, Total	6.03B	7.21B	8.41B	8.3B	10.24B
Other Receivables	2.76B	2.71B	3.53B	4.79B	4.06B
Total Receivables	8.8B	9.92B	11.94B	13.09B	14.3B
Inventory	8.98B	4.7B	5.42B	5.29B	6.56B
Prepaid Expenses	1.51B	1.33B	1.62B	1.74B	2.03B
Restricted Cash	-	162M	102M	129M	22M
Other Current Assets, Total	556M	236M	116M	54M	90M
Total Current Assets	26.24B	22.59B	25.05B	25.83B	28.72B
Gross Property Plant And Equipment	18.5B	17.19B	19.1B	20.52B	25.24B
Accumulated Depreciation	-8.32B	-7.74B	-8.6B	-8.88B	-10.54B
Net Property Plant And Equipment	10.17B	9.45B	10.5B	11.65B	14.7B
Long-term Investments	1.26B	1.14B	1.68B	1.9B	2.52B
Goodwill	20B	19.82B	20.05B	21.02B	21.24B
Other Intangibles, Total	42.39B	39.31B	38.09B	37.18B	37.85B
Deferred Tax Assets Long-Term	4.33B	3.26B	4.72B	5.35B	5.82B
Other Long-Term Assets, Total	972M	909M	1.03B	1.11B	3.22B
Total Assets	105B	96.48B	101B	104B	114B
Liabilities
Accounts Payable, Total	2.82B	2.55B	3.27B	3.64B	3.82B
Accrued Expenses, Total	12.36B	13.43B	15.74B	16.09B	19.3B
Short-term Borrowings	411M	5.31B	3.53B	330M	644M
Current Portion of Long-Term Debt	2.25B	960M	2.59B	2.06B	2.54B
Current Portion of Leases	233M	228M	271M	339M	382M
Current Income Taxes Payable	916M	896M	1.58B	1.41B	1.08B
Unearned Revenue Current, Total	1.18B	269M	251M	126M	144M
Other Current Liabilities	2.42B	2.65B	3.31B	3.88B	2.7B
Total Current Liabilities	22.59B	26.29B	30.54B	27.87B	30.62B
Long-Term Debt	29.72B	23.91B	22.4B	26.62B	24.72B
Long-Term Leases	754M	725M	857M	1.11B	1.42B
Unearned Revenue Non Current	26M	14M	7M	-	55M
Pension & Other Post Retirement Benefits	2.45B	1.17B	1.52B	1.33B	1.1B
Deferred Tax Liability Non Current	6.21B	2.94B	2.84B	3.3B	3.5B
Other Non Current Liabilities	4.32B	4.37B	3.78B	2.93B	3.94B
Total Liabilities	66.08B	59.42B	61.95B	63.16B	65.36B
Common Stock, Total	387M	387M	388M	388M	388M
Additional Paid In Capital	35.13B	35.16B	35.19B	35.23B	35.27B
Retained Earnings	3.64B	3.12B	4.52B	7.23B	12.6B
Comprehensive Income and Other	111M	-1.62B	-949M	-2.06B	414M
Total Common Equity	39.27B	37.04B	39.14B	40.79B	48.67B
Minority Interest	19M	21M	23M	85M	52M
Total Equity	39.29B	37.06B	39.17B	40.87B	48.72B
Total Liabilities And Equity	105B	96.48B	101B	104B	114B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	1.55B	1.55B	1.55B	1.55B	1.55B
ECS Total Common Shares Outstanding	1.55B	1.55B	1.55B	1.55B	1.55B
Book Value / Share	25.34	23.9	25.25	26.3	31.38
Tangible Book Value	-23.12B	-22.09B	-18.99B	-17.42B	-10.42B
Tangible Book Value Per Share	-14.92	-14.25	-12.25	-11.23	-6.72
Total Debt	33.36B	31.14B	29.65B	30.46B	29.7B
Net Debt	26.96B	24.89B	23.79B	24.94B	23.98B
Debt Equivalent of Unfunded Proj. Benefit Obligation	2.5B	1.12B	1.48B	1.27B	1.05B
Debt Equivalent Oper. Leases	48M	-	-	-	-
Minority Interest, Total (Incl. Fin. Div)	19M	21M	23M	85M	52M
Equity Method Investments, Total	69M	76M	147M	268M	302M
Account Code - Inventory Valuation	3	3	3	3	3
Inventories - Raw Materials, Total	1.76B	1.42B	1.53B	1.49B	1.86B
Inventories - Work In Process, Total	5.22B	1.86B	2.32B	2.28B	2.78B
Inventories - Finished Goods, Total	2.01B	1.41B	1.57B	1.52B	1.92B
Land - (BS)	6.38B	5.44B	6.47B	6.58B	7.24B
Machinery, Total	7.9B	7.56B	8.7B	8.85B	10.32B
Full Time Employees	83.1K	83.5K	89.9K	94.3K	96.1K
Accumulated Allowance for Doubtful Accounts (Supple)	23M	59M	45M	33M	52M

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	112M	3.29B	5.96B	7.04B	10.22B
Depreciation & Amortization - CF	959M	1.1B	1B	1.14B	1.28B
Amortization of Goodwill and Intangible Assets - (CF)	3.08B	4.08B	3.85B	3.84B	4.11B
Depreciation & Amortization, Total	4.04B	5.18B	4.85B	4.98B	5.39B
Amortization of Deferred Charges, Total - (CF)	63M	76M	280M	200M	236M
(Gain) Loss From Sale Of Asset	-513M	-216M	-292M	-60M	-155M
(Gain) Loss on Sale of Investments - (CF)	-776M	-	-	-	-
Asset Writedown & Restructuring Costs	2.43B	226M	456M	1.62B	243M
(Income) Loss On Equity Investments - (CF)	64M	5M	12M	28M	7M
Stock-Based Compensation (CF)	45M	27M	-71M	42M	366M
Other Operating Activities, Total	-1.52B	-2.53B	-1.15B	-1.1B	-602M
Change In Accounts Receivable	-961M	-1.35B	-1.42B	-1.62B	-1.73B
Change In Inventories	1.58B	3.94B	-669M	-131M	-755M
Change In Accounts Payable	1.4B	1.16B	2.39B	862M	1.35B
Cash from Operations	5.96B	9.81B	10.34B	11.86B	14.58B
Capital Expenditure	-1.09B	-1.09B	-1.36B	-1.92B	-2.81B
Sale of Property, Plant, and Equipment	13M	282M	132M	55M	13M
Cash Acquisitions	-10.12B	-1.04B	-1.1B	-3.78B	-1.23B
Sale (Purchase) of Intangible assets	-522M	-1.03B	-2.13B	-2.54B	-2.96B
Investment in Marketable and Equity Securities, Total	605M	-143M	-87M	-133M	-108M
Other Investing Activities, Total	54M	60M	477M	343M	286M
Cash from Investing	-11.06B	-2.96B	-4.06B	-7.98B	-6.81B
Short Term Debt Issued, Total	-	74M	161M	-	364M
Long-Term Debt Issued, Total	12.93B	-	3.82B	6.49B	15M
Total Debt Issued	12.93B	74M	3.98B	6.49B	379M
Short Term Debt Repaid, Total	-276M	-	-	-31M	-
Long-Term Debt Repaid, Total	-5B	-1.52B	-5.21B	-4.97B	-2.4B
Total Debt Repaid	-5.28B	-1.52B	-5.21B	-5B	-2.4B
Issuance of Common Stock	29M	29M	33M	38M	40M
Repurchase of Common Stock	-	-	-	-81M	-521M
Common Dividends Paid	-3.86B	-4.36B	-4.48B	-4.63B	-4.85B
Common & Preferred Stock Dividends Paid	-3.86B	-4.36B	-4.48B	-4.63B	-4.85B
Other Financing Activities, Total	-178M	-1.05B	-886M	-817M	-195M
Cash from Financing	3.65B	-6.82B	-6.57B	-4B	-7.54B
Foreign Exchange Rate Adjustments	-62M	-80M	-60M	-93M	46M
Net Change in Cash	-1.51B	-55M	-346M	-208M	269M
Supplemental Items
Cash Interest Paid	721M	849M	1.08B	1.31B	1.32B
Cash Income Tax Paid (Refund)	1.74B	1.62B	2.37B	2.75B	2.84B
Levered Free Cash Flow	-896M	12.36B	9.5B	8.46B	7.87B
Unlevered Free Cash Flow	-412M	12.94B	10.06B	9.22B	8.58B
Change In Net Working Capital	6.52B	-3.59B	-1.52B	121M	792M
Net Debt Issued / Repaid	7.65B	-1.44B	-1.23B	1.49B	-2.02B

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	3.5	5.55	6.6	7.88	8.19
Return on Total Capital	5.42	7.95	9.52	11.53	11.93
Return On Equity %	0.42	8.63	15.64	17.59	22.84
Return on Common Equity	0.41	8.62	15.63	17.6	22.86
Margin Analysis
Gross Profit Margin %	73.81	80.57	82.45	82.18	81.71
SG&A Margin	38.65	39.39	39.35	35.98	34.17
EBITDA Margin %	23.03	31.33	32.76	32.49	32.82
EBITA Margin %	21.09	29.41	31.17	31.01	31.33
EBIT Margin %	12.86	20.21	22.78	23.91	24.33
Income From Continuing Operations Margin %	0.31	7.42	13.01	13.02	17.42
Net Income Margin %	0.3	7.41	13	13.01	17.41
Net Avail. For Common Margin %	0.3	7.41	13	13.01	17.41
Normalized Net Income Margin	5.87	10.89	12.51	13.47	13.82
Levered Free Cash Flow Margin	-2.4	27.88	20.74	15.65	13.39
Unlevered Free Cash Flow Margin	-1.1	29.17	21.96	17.05	14.61
Asset Turnover
Asset Turnover	0.43	0.44	0.46	0.53	0.54
Fixed Assets Turnover	3.92	4.52	4.59	4.88	4.46
Receivables Turnover (Average Receivables)	7.61	6.7	5.87	6.47	6.34
Inventory Turnover (Average Inventory)	1.51	1.26	1.59	1.8	1.81
Short Term Liquidity
Current Ratio	1.16	0.86	0.82	0.93	0.94
Quick Ratio	0.67	0.61	0.58	0.67	0.65
Operating Cash Flow to Current Liabilities	0.26	0.37	0.34	0.43	0.48
Days Sales Outstanding (Average Receivables)	47.98	54.49	62.22	56.55	57.6
Days Outstanding Inventory (Average Inventory)	242.25	289.7	229.78	203.39	201.16
Average Days Payable Outstanding	63.98	226.24	121.12	133.02	113.31
Cash Conversion Cycle (Average Days)	226.24	117.96	170.89	126.92	145.45
Long Term Solvency
Total Debt/Equity	84.92	84.02	75.7	74.53	60.97
Total Debt / Total Capital	45.92	45.66	43.08	42.7	37.88
LT Debt/Equity	77.56	66.47	59.39	67.86	53.65
Long-Term Debt / Total Capital	41.94	36.12	33.8	38.88	33.33
Total Liabilities / Total Assets	62.71	61.59	61.27	60.71	57.29
EBIT / Interest Expense	6.2	9.77	8.56	9.22	10.47
EBITDA / Interest Expense	11.41	15.42	12.54	12.77	14.42
(EBITDA - Capex) / Interest Expense	10	14.23	11.42	11.39	12.36
Total Debt / EBITDA	3.77	2.2	1.94	1.7	1.51
Net Debt / EBITDA	3.05	1.76	1.56	1.39	1.22
Total Debt / (EBITDA - Capex)	4.3	2.39	2.13	1.91	1.76
Net Debt / (EBITDA - Capex)	3.47	1.91	1.71	1.56	1.42
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	40.58	18.53	3.29	18.03	8.63
Gross Profit, 1 Yr. Growth %	29.23	29.38	5.71	17.64	8.01
EBITDA, 1 Yr. Growth %	27.3	51.91	7.64	23.5	9.75
EBITA, 1 Yr. Growth %	29.82	54.85	9.07	24.26	9.74
EBIT, 1 Yr. Growth %	16.01	67.75	15.78	34.01	10.54
Earnings From Cont. Operations, 1 Yr. Growth %	-96.34	2.76K	81.02	18.12	45.33
Net Income, 1 Yr. Growth %	-96.5	2.84K	81.11	18.14	45.34
Normalized Net Income, 1 Yr. Growth %	16.21	91.14	17.89	39.07	11.42
Diluted EPS Before Extra, 1 Yr. Growth %	-96.76	2.57K	80.57	18.11	45.33
Accounts Receivable, 1 Yr. Growth %	58.46	19.58	16.57	-1.25	23.31
Inventory, 1 Yr. Growth %	123.24	-47.69	15.43	-2.51	24
Net Property, Plant and Equip., 1 Yr. Growth %	14.06	-7.1	11.14	10.9	26.24
Total Assets, 1 Yr. Growth %	57.9	-8.43	4.8	2.88	9.65
Tangible Book Value, 1 Yr. Growth %	34.63	-4.44	-14.02	-8.31	-40.16
Common Equity, 1 Yr. Growth %	151.36	-5.68	5.69	4.2	19.32
Cash From Operations, 1 Yr. Growth %	24.26	64.48	5.48	14.65	22.88
Capital Expenditures, 1 Yr. Growth %	13.53	0	24.75	41.37	46.05
Levered Free Cash Flow, 1 Yr. Growth %	-127.15	-2.29K	-24.67	-6.08	-7.04
Unlevered Free Cash Flow, 1 Yr. Growth %	-110.93	-16.35K	-22.41	-3.64	-6.95
Dividend Per Share, 1 Yr. Growth %	2.5	1.05	0	6.9	3.23
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	23.87	29.08	10.65	10.42	13.23
Gross Profit, 2 Yr. CAGR %	18.9	29.31	21.92	11.55	12.73
EBITDA, 2 Yr. CAGR %	24.32	40.99	49.67	13.06	16.22
EBITA, 2 Yr. CAGR %	26.55	43.87	54.57	14.05	16.56
EBIT, 2 Yr. CAGR %	25.24	43.21	89.78	21.13	21.39
Earnings From Cont. Operations, 2 Yr. CAGR %	-69.39	2.34	619.96	46.22	31.02
Net Income, 2 Yr. CAGR %	-71.04	1.43	629.18	46.27	31.04
Normalized Net Income, 2 Yr. CAGR %	35.33	54.34	139.59	24.04	24.11
Diluted EPS Before Extra, 2 Yr. CAGR %	-72.26	-6.93	594.53	46.04	31.02
Accounts Receivable, 2 Yr. CAGR %	29.7	37.66	18.07	7.29	10.35
Inventory, 2 Yr. CAGR %	67.73	8.06	-22.3	6.08	9.95
Net Property, Plant and Equip., 2 Yr. CAGR %	10.47	2.94	1.61	11.02	18.32
Total Assets, 2 Yr. CAGR %	31.02	20.25	-2.03	3.84	6.21
Tangible Book Value, 2 Yr. CAGR %	9.23	13.43	-9.35	-11.21	-25.93
Common Equity, 2 Yr. CAGR %	72.96	53.97	-0.16	4.94	11.5
Cash From Operations, 2 Yr. CAGR %	41.72	42.96	31.71	9.97	18.7
Capital Expenditures, 2 Yr. CAGR %	5.57	6.55	11.69	32.8	43.69
Levered Free Cash Flow, 2 Yr. CAGR %	-62.01	89.55	126.88	-17.68	-6.72
Unlevered Free Cash Flow, 2 Yr. CAGR %	-75.22	82.08	150.11	-15.26	-5.47
Dividend Per Share, 2 Yr. CAGR %	1.24	1.77	0.52	3.39	5.05
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	19.2	22.07	19.84	13.06	9.82
Gross Profit, 3 Yr. CAGR %	16.24	22.29	20.91	20.47	10.36
EBITDA, 3 Yr. CAGR %	24.53	35.58	29.01	37.89	11.94
EBITA, 3 Yr. CAGR %	27.41	38.33	31.35	41.04	12.59
EBIT, 3 Yr. CAGR %	40.61	42.96	33.66	64.64	17.49
Earnings From Cont. Operations, 3 Yr. CAGR %	-61.72	38.97	23.77	294.14	45.93
Net Income, 3 Yr. CAGR %	-62.68	35.05	23.05	297.51	45.96
Normalized Net Income, 3 Yr. CAGR %	84.75	59.13	41.38	93.98	19.68
Diluted EPS Before Extra, 3 Yr. CAGR %	-64.05	27.16	16.08	284.79	45.8
Accounts Receivable, 3 Yr. CAGR %	26.28	26.24	30.23	11.24	12.38
Inventory, 3 Yr. CAGR %	45.94	13.75	10.46	-16.19	11.75
Net Property, Plant and Equip., 3 Yr. CAGR %	11.08	4.27	5.6	4.62	15.88
Total Assets, 3 Yr. CAGR %	20.21	16.27	14.86	-0.42	5.74
Tangible Book Value, 3 Yr. CAGR %	2.93	4.47	3.42	-9.01	-22.15
Common Equity, 3 Yr. CAGR %	46.58	41.3	35.82	1.27	9.53
Cash From Operations, 3 Yr. CAGR %	31.57	48.93	29.18	25.76	14.12
Capital Expenditures, 3 Yr. CAGR %	1.51	3.68	12.3	20.82	37.08
Levered Free Cash Flow, 3 Yr. CAGR %	-37.65	25.78	40.28	66.13	-14.28
Unlevered Free Cash Flow, 3 Yr. CAGR %	-53.76	24.52	37.12	78.98	-12.58
Dividend Per Share, 3 Yr. CAGR %	0.83	1.18	1.18	2.6	3.34
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	10.22	14.57	15.71	17.27	17.15
Gross Profit, 5 Yr. CAGR %	7.76	14.28	16.52	17.86	17.56
EBITDA, 5 Yr. CAGR %	7.2	18.26	27.46	25.8	22.5
EBITA, 5 Yr. CAGR %	7.4	19.15	30.2	27.75	23.9
EBIT, 5 Yr. CAGR %	4.26	19.45	43.23	33.33	26.74
Earnings From Cont. Operations, 5 Yr. CAGR %	-49.22	2.8	23.8	41.83	26.62
Net Income, 5 Yr. CAGR %	-49.76	1.84	22.54	39.43	26.19
Normalized Net Income, 5 Yr. CAGR %	4.88	25.34	75.1	43.47	31.98
Diluted EPS Before Extra, 5 Yr. CAGR %	-50.87	-2.3	17.52	34.4	21.84
Accounts Receivable, 5 Yr. CAGR %	18.48	20.81	22.93	18.29	21.88
Inventory, 5 Yr. CAGR %	30.94	9.14	13.42	10.62	10.26
Net Property, Plant and Equip., 5 Yr. CAGR %	8.23	4.41	7.19	6.92	10.52
Total Assets, 5 Yr. CAGR %	11	8.78	10.76	11.13	11.32
Tangible Book Value, 5 Yr. CAGR %	-1.07	-0.85	-2.17	-2.11	-9.5
Common Equity, 5 Yr. CAGR %	21.46	19.88	25.71	25.45	25.52
Cash From Operations, 5 Yr. CAGR %	7.54	22.35	31.63	31.92	24.88
Capital Expenditures, 5 Yr. CAGR %	-5.48	-3.83	5.47	14.47	23.94
Levered Free Cash Flow, 5 Yr. CAGR %	-27.5	24.13	20.77	6.37	17.98
Unlevered Free Cash Flow, 5 Yr. CAGR %	-38.97	22.92	19.3	6.6	17.07
Dividend Per Share, 5 Yr. CAGR %	0.5	0.7	0.7	2.06	2.71